Mobile Site ›

The Use of Genetics in Guiding Therapy

CYP2C19 and Response to Clopidogrel (cont)

Slide 9

June 2012

CYP2C19 loss of function alleles have been associated with an increased rate of subsequent cardiovascular events and death in patients taking clopidogrel. For example, this landmark study showed a relative 53% increased risk of death from cardiovascular causes, MI, or stroke, and a 3-fold increased risk of stent thrombosis in patients who were taking clopidogrel and had a CYP2C19 loss of function allele, compared to patients taking clopidogrel without CYP2C19 loss of function alleles. Higher risks for cardiovascular events and stent thrombosis have been demonstrated for both heterozygote and homozygote *2 carriers who are given clopidogrel. What these studies and others have demonstrated is that individuals with CYP2C19 loss of function alleles who are taking clopidogrel might not receive benefit from the drug.

CYP2C19 and Response to Clopidogrel (cont)


Jump to section: